Skip to main content

Guardian Pharmacy Services Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

GRDN$49.85+6.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Cash Flows

(UNAUDITED)

Nine Months EndedSeptember 30,
(In thousands)20232024
Operating activities
Net income (loss)$23,161$(82,874)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization13,52014,619
Share-based compensation expense16,632128,029
Provision for losses on accounts receivable3,7074,240
Other257(31)
Changes in operating assets and liabilities:
Accounts receivable(11,958)(17,285)
Inventories3,571(6,226)
Other current assets(2,173)768
Accounts payable10,21314,158
Accrued compensation(2,396)(3,373)
Other operating liabilities1,731(16,402)
Net cash provided by operating activities56,26535,623
Investing activities
Purchases of property and equipment(11,793)(11,867)
Payment for acquisitions(985)(12,460)
Other484544
Net cash used in investing activities(12,294)(23,783)
Financing activities
Proceeds from equity offering, net of underwriter fees—119,784
Payments of equity offering costs—(538)
Payments to Class B common stock stockholders—(55,176)
Borrowings from notes payable—15,000
Repayment of notes payable(3,000)(3,750)
Borrowings from line of credit198,000189,300
Repayments of line of credit(196,000)(188,300)
Principal payments on finance lease obligations(3,091)(3,309)
Contributions from non-controlling interests5382,107
Distributions to non-controlling interests(11,732)(14,279)
Member distributions(28,422)(36,050)
Other(250)(160)
Net cash provided by (used in) financing activities(43,957)24,629
Net change in cash and cash equivalents1436,469
Cash and cash equivalents, beginning of period607752
Cash and cash equivalents, end of period$621$37,221
Supplemental disclosure of cash flow information
Cash paid during the year for interest$2,082$2,851
Supplemental disclosure of non-cash investing and financing activities
Purchases of property and equipment through finance leases$5,562$2,256
Accrued and capitalized offering costs recorded to additional paid-in capital$—$12,509
Non-cash equity contributions from non-controlling members$225$4,989
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.